TY - JOUR T1 - Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors JF - Open Heart JO - Open Heart DO - 10.1136/openhrt-2021-001655 VL - 8 IS - 1 SP - e001655 AU - James J DiNicolantonio AU - Jorge Barroso-Aranda AU - Mark F McCarty Y1 - 2021/04/01 UR - http://openheart.bmj.com/content/8/1/e001655.abstract N2 - Ivermectin, a drug commonly used to treat a range of parasitic infections, has been shown to halve the mortality elicited by a fatal dose of lipopolysaccharide in mice, in an oral dose (4 mg/kg) that can be extrapolated to 2–4 times the standard clinical dose in humans (0.2 mg/kg).1 It has been suggested that this phenomenon is highly pertinent to the clinical utility of ivermectin in the cytokine storm phase of COVID-19, which has been documented in a number of clinical studies.2 A meta-analysis of 18 clinical studies to date examining the impact of ivermectin therapy in hospitalised COVID-19 patients has observed a roughly 68% reduction in mortality associated with its usage.3The basis of ivermectin’s potent anti-inflammatory activity remains unclear. However, it is notable that ivermectin can act as a partial agonist for glycine-gated strychnine-inhibitable chloride channels, which are expressed by a number of types of immune … ER -